Clinical Trials Browser

Simpson-Golabi-Behmel syndrome × Clear all

NCT06427941 2026-03-18

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

Gastrointestinal

Simpson-Golabi-Behmel syndrome, Carcinoma, Hepatocellular

NCT06715839 2025-12-31

Target-specific immunoPET Imaging of Digestive System Carcinoma

Phase NA Recruiting

Gastrointestinal

Simpson-Golabi-Behmel syndrome, Appendiceal Neoplasms, Bile Duct Neoplasms, Colonic Neoplasms, Digestive System Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Liver Neoplasms, Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

NCT06478693 2025-12-18

A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC

Phase 1 Recruiting

Gastrointestinal

Simpson-Golabi-Behmel syndrome, Carcinoma, Hepatocellular, Liver Neoplasms

NCT05263830 2025-12-16

IMMUNOGLYPIC

Gastrointestinal

Simpson-Golabi-Behmel syndrome, Carcinoma, Hepatocellular

NCT06687941 2025-03-21

A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors

Phase 1 Recruiting

GastrointestinalThoracic

Simpson-Golabi-Behmel syndrome, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasm Metastasis, Neoplasms

NCT04728139 2022-01-13

Assessment of Glypican 3 as Apredictive Marker in Colorectal Cancer Patients

Phase NA Unknown

Gastrointestinal

Simpson-Golabi-Behmel syndrome, Colorectal Neoplasms

NCT04121273 2021-03-03

GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC

Phase 1 Unknown

Gastrointestinal

Simpson-Golabi-Behmel syndrome, Carcinoma, Hepatocellular

NCT02723942 2020-07-16

CAR-T Cell Immunotherapy for HCC Targeting GPC3

Phase 1/2 Withdrawn

Gastrointestinal

Simpson-Golabi-Behmel syndrome, Carcinoma, Hepatocellular